Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Multiple Clostridium Difficile Strains Cause Severe Patient Outcomes

By LabMedica International staff writers
Posted on 08 Sep 2015
Clostridium difficile is the most common cause of hospital acquired infections in the USA and the incidence of C. More...
difficile infection (CDI) has increased dramatically since 2001, coinciding with the emergence of the epidemic ribotype 027 (R027).

The high mortality rate associated with R027 led to it being described as a hypervirulent strain and since that characterization, additional ribotypes of C. difficile have been described as hypervirulent using similar criteria, but the impact of C. difficile ribotype on disease outcomes remains unclear, especially in endemic rather than epidemic settings.

Scientists at the University of Houston College of Pharmacy (Houston, TX, USA) and their colleagues collected and cultured stool samples that tested positive for C. difficile toxin from patients who presented to any of seven different local hospitals from 2011 to 2013. The study included 715 patients aged 61 ± 18 years with females making up 63% of the study population.

Enzyme-linked immunoassay or a polymerase-chain reaction (PCR) detection of the tcdB gene in unformed stool was the diagnostic methodology used at all study sites during the study period. C. difficile toxin-positive stool samples were plated onto cefoxitin-cycloserine-fructose agar (CCFA) plates and incubated under strict anaerobic conditions for 48 to 72 hours. The growth of toxigenic C. difficile was confirmed using multiplex PCR to determine the presence of tcdA, tcdB, and binary toxin genes and fluorescent ribotyping was performed.

In this large multicenter study, C. difficile R027 was the most common ribotype and was associated with severe CDI presentation and severe CDI outcomes. Although R027 was independently associated with severe disease, R027 was not independently associated with severe outcomes. No single strain was more virulent than the others. The ribotype 014-020 was associated with significantly lower incidence of severe CDI and severe CDI outcomes compared with other ribotypes.

Samuel L. Aitken, PharmD, the lead author of the study, said, “Clinical severity markers of CDI, such as white blood cell count and albumin level, a protein in blood, are more important predictors of severe outcomes than any specific strain, especially in hospitals with no single predominant strain. Strain typing remains a valuable source of information for tracking emergence of different strains and may potentially influence treatment decisions, but clinical severity markers appear to be more important predictors for the determining the severity of CDI patient outcomes.” The study was published on August 20, 2015, in the journal Infection Control & Hospital Epidemiology.

Related Links:
University of Houston College of Pharmacy



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.